Could a change in diet be beneficial to people with autoimmune diseases such as lupus? A team of researchers have revealed how a dietary intervention can help prevent the development of this autoimmune disease in susceptible mice. The study was published in Cell Host & Microbe.
For the study, the research team used mouse models of lupus. They first identified a single bacterium, Lactobacillus reuteri, in the gut of the mice that triggered an immune response leading to the disease. Specifically, in lupus-prone mice, L. reuteri stimulated immune cells known as dendritic cells, as well as immune system pathways that exacerbated disease development.
To investigate the potential impact of diet on this process, first author fed the mice "resistant starch" (RS)-- a diet that mimics a high-fiber diet in humans. The resistant starch is not absorbed in the small intestine but ferments in the large intestine, enriching good bacteria and causing the secretion of short-chain fatty acids. This, in turn, suppresses both the growth and movement of L. reuteri bacteria outside the gut that would otherwise lead to autoimmune disease.
While more research is needed to discern how the findings translate to humans, the study details an important link between diet, gut bacteria, and autoimmunity. L. reuteri colonization worsened autoimmune manifestations, notably increasing plasmacytoid dendritic cells (pDCs) and interferon signaling. However, RS suppressed the abundance and translocation of L. reuteri via short-chain fatty acids, which inhibited its growth. "We dissected, molecularly, how diets can work on the gut microbiome," said the lead author. "We identified a pathway that is driving autoimmune disease and mitigated by the diet." Authors show that RS decreased pDCs, interferon pathways, organ involvement, and mortality.
The study also found an imbalance of gut microbes in a subset of lupus patients that was similar to what they observed in lupus-prone mice not given the starch diet. In this subset of lupus patients, the high-fiber diet could potentially be beneficial to prevent or ameliorate the condition, in addition to other diseases that activate the same immune pathway, the lead author noted. "It may have implications beyond lupus."
https://news.yale.edu/2018/12/20/yale-led-team-examines-impact-diet-intervention-autoimmunity-mice
https://www.cell.com/cell-host-microbe/fulltext/S1931-3128(18)30591-2
Latest News
Mutant Huntingtin stalls ribosomes and represses protein synthesis
Epigraph vaccine protects against dozen-plus flu strains
Origin of childhood malignant rhabdoid brain/kidney cancer discovered
Repurposing drugs using artificial intelligence to combat Alzheimer's disease
Resolving dysfunctional macrophages to control neuropathic pain
Other Top Stories
SISSOR to improve accuracy of single-cell genome sequencing
High-throughput mouse behavior and physiology platform!
Amnesic mice retain silent memory engrams
Cerebrospinal fluid exits mainly through lymph system!
Revolutionary imaging technique uses CRISPR to map DNA mutations
Protocols
Dual-Angle Protocol for Doppler Optical Coherence Tomography to Improve Retinal Blood Flow Measur…
Detection of protein SUMOylation in vivo
In vivo analysis of protein sumoylation induced by a viral protein: Detection of HCMV pp71-induce…
Determination of SUMOylation sites
miR-Selection 3'UTR Target Selection Kit
Publications
cAMP at Perinuclear mAKAPa Signalosomes Is Regulated by Local Ca21 Signaling in Primary Hippocamp…
High-resolution phenotyping of early acute rejection reveals a conserved alloimmune signature
Mutant Huntingtin stalls ribosomes and represses protein synthesis in a cellular model of Hunting…
Epigraph hemagglutinin vaccine induces broad cross-reactive immunity against swine H3 influenza v…
Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours
Presentations
Genetics and Huntington Disease
Gaucher disease
Glycogen Storage Disease
Tay-Sach's Disease
Guillain-Barré syndrome
Posters
ASCO-2020-GASTROINTESTINAL CANCER–COLORECTAL AND ANAL
ASCO-2020-DEVELOPMENTAL THERAPEUTICS–IMMUNOTHERAPY
ASCO-2020-DEVELOPMENTAL THERAPEUTICS–MOLECULARLY TARGETED AGENTS AND TUMOR BIOLOGY
ASCO-2020-CENTRAL NERVOUS SYSTEM TUMORS
ASCO-2020-DEVELOPMENTAL THERAPEUTICS–IMMUNOTHERAPY